vs
Side-by-side financial comparison of CALLAN JMB INC. (CJMB) and InMed Pharmaceuticals Inc. (INM). Click either name above to swap in a different company.
CALLAN JMB INC. is the larger business by last-quarter revenue ($1.2M vs $820.2K, roughly 1.4× InMed Pharmaceuticals Inc.). CALLAN JMB INC. runs the higher net margin — -223.8% vs -247.3%, a 23.5% gap on every dollar of revenue.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
CJMB vs INM — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $820.2K |
| Net Profit | $-2.6M | $-2.0M |
| Gross Margin | 30.3% | 22.5% |
| Operating Margin | -216.6% | -247.3% |
| Net Margin | -223.8% | -247.3% |
| Revenue YoY | — | -26.2% |
| Net Profit YoY | — | 21.2% |
| EPS (diluted) | $-0.58 | $-0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | $820.2K | ||
| Q3 25 | $1.4M | $1.1M | ||
| Q2 25 | $1.7M | $1.3M | ||
| Q1 25 | $1.4M | $1.3M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $1.2M |
| Q4 25 | $-2.6M | $-2.0M | ||
| Q3 25 | $-2.7M | $-1.7M | ||
| Q2 25 | $-1.4M | $-1.8M | ||
| Q1 25 | $-1.2M | $-2.1M | ||
| Q4 24 | — | $-2.6M | ||
| Q3 24 | — | $-1.7M | ||
| Q2 24 | — | $-1.9M | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | 30.3% | 22.5% | ||
| Q3 25 | 34.1% | 36.0% | ||
| Q2 25 | 38.6% | 44.2% | ||
| Q1 25 | 42.5% | 13.9% | ||
| Q4 24 | — | 41.5% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | — | 36.3% | ||
| Q1 24 | — | 24.7% |
| Q4 25 | -216.6% | -247.3% | ||
| Q3 25 | -129.9% | -154.2% | ||
| Q2 25 | -84.2% | -137.1% | ||
| Q1 25 | -85.4% | -168.1% | ||
| Q4 24 | — | -231.6% | ||
| Q3 24 | — | -132.7% | ||
| Q2 24 | — | -150.5% | ||
| Q1 24 | — | -146.9% |
| Q4 25 | -223.8% | -247.3% | ||
| Q3 25 | -188.8% | -154.2% | ||
| Q2 25 | -83.9% | -137.1% | ||
| Q1 25 | -85.6% | -168.1% | ||
| Q4 24 | — | -231.6% | ||
| Q3 24 | — | -132.7% | ||
| Q2 24 | — | -151.0% | ||
| Q1 24 | — | -146.9% |
| Q4 25 | $-0.58 | $-0.51 | ||
| Q3 25 | $-0.61 | $-0.44 | ||
| Q2 25 | $-0.31 | $-0.07 | ||
| Q1 25 | $-0.32 | $-1.94 | ||
| Q4 24 | — | $-3.64 | ||
| Q3 24 | — | $-2.71 | ||
| Q2 24 | — | $2.39 | ||
| Q1 24 | — | $-3.58 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.1M | $7.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3M | $9.6M |
| Total Assets | $5.8M | $11.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.1M | $7.0M | ||
| Q3 25 | $2.8M | $9.4M | ||
| Q2 25 | $4.2M | $11.1M | ||
| Q1 25 | $5.2M | $4.7M | ||
| Q4 24 | — | $3.5M | ||
| Q3 24 | — | $5.6M | ||
| Q2 24 | — | $6.6M | ||
| Q1 24 | — | — |
| Q4 25 | $2.3M | $9.6M | ||
| Q3 25 | $4.2M | $11.6M | ||
| Q2 25 | $5.8M | $13.4M | ||
| Q1 25 | $6.8M | $7.0M | ||
| Q4 24 | — | $6.2M | ||
| Q3 24 | — | $8.4M | ||
| Q2 24 | — | $9.2M | ||
| Q1 24 | — | $11.1M |
| Q4 25 | $5.8M | $11.2M | ||
| Q3 25 | $7.7M | $13.4M | ||
| Q2 25 | $9.0M | $15.6M | ||
| Q1 25 | $8.5M | $9.3M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $10.5M | ||
| Q2 24 | — | $11.8M | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-659.0K | $-2.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-659.0K | $-2.4M | ||
| Q3 25 | $-1.8M | $-1.6M | ||
| Q2 25 | $-563.3K | $-1.8M | ||
| Q1 25 | $-1.6M | $-1.7M | ||
| Q4 24 | — | $-2.5M | ||
| Q3 24 | — | $-1.8M | ||
| Q2 24 | — | $-1.0M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | $-1.9M | — | ||
| Q2 25 | $-995.8K | — | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | -133.5% | — | ||
| Q2 25 | -59.8% | — | ||
| Q1 25 | -108.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -165.0% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 26.0% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CJMB
| Governmental | $1.1M | 91% |
| Other | $106.5K | 9% |
INM
Segment breakdown not available.
